Recent developments include strategic acquisitions and partnerships, product launches, and legal outcomes that shape Vystar's business activities.

• Vystar submitted a binding letter of intent to acquire a stake in GoPaid.com LLC and form a strategic partnership with Capital R3alm to launch R3alm Oracle and R3alm Collectibles platform [N3][N2].
• The company reported a court victory awarding $497,439.58 in legal fees and costs against EMA Financial, Inc. [N4].
• Vystar’s Vytex Cloud Bed-in-a-Box product was made available for sale and later restarted sales [N5][N6].
• Vystar introduced a new RxAir-800 replacement cartridge with extended life UV-C bulb [N7].
• The company introduced an ultrasoft latex mattress topper with Vytex 55 density latex into the Vytex.com store [N8].
• Recent news unrelated to Vystar's core business includes commodity market updates such as wheat price movements [N1].

Vystar's patented Vytex technology addresses allergenic concerns in natural rubber latex products, potentially appealing to manufacturers and consumers seeking safer latex alternatives. The FDA clearance of RxAir products as Class II medical devices supports market acceptance in the air purification sector. Strategic partnerships, such as the planned acquisition of a stake in GoPaid.com and collaboration with Capital R3alm to launch a collectibles platform, indicate diversification and innovation efforts. Product launches including the Vytex Cloud Bed-in-a-Box and new RxAir replacement cartridges demonstrate ongoing product development. Legal victories enhancing financial resources may support operational stability [N2][N3][N4][N5][N6][N7][N8][S1].

Vystar faces significant risks including low liquidity and a net loss position, with a current ratio of 0.06 and cash ratio of 0.04 as of June 30, 2026, indicating potential financial distress [S2]. The company has a limited operating history and a single employee as of end 2025, which may constrain execution capacity [S1]. Market acceptance of Vytex NRL depends on manufacturers' willingness to adopt the technology and consumer demand, both sensitive to economic conditions and discretionary spending [S1]. Competition from synthetic latex and other air purification providers is intense, with pricing pressures and regulatory uncertainties for future product approvals. The discontinued operations of Rotmans Furniture reflect challenges in diversification efforts [S1].

Vystar's moat is based on its proprietary, multi-patented Vytex Natural Rubber Latex technology that significantly reduces allergenic proteins, differentiating it in the natural rubber latex market. The FDA clearance of its RxAir air purification products as Class II medical devices provides regulatory credibility and market differentiation. The company's portfolio of patents and trademarks across multiple countries supports intellectual property protection. However, the company operates in highly competitive markets with synthetic latex alternatives and numerous air purifier manufacturers, which may limit pricing power and market share expansion. The company's relatively small scale and limited operating history also constrain its competitive moat [S1].

• Financial Liquidity Risk: As of June 30, 2026, Vystar reported a current ratio of 0.06 and cash ratio of 0.04, indicating limited liquidity to cover short-term liabilities, which may impact ongoing operations and capital needs [S2].
• Market Acceptance Risk: The Vytex business depends on manufacturers adopting the patented latex technology and consumer demand for products made with Vytex NRL, which can be affected by economic downturns and discretionary spending patterns [S1].
• Competitive Risk: Vystar operates in highly competitive markets for air purification and natural rubber latex, facing competition from synthetic alternatives and numerous manufacturers, which may pressure pricing and market share [S1].
• Regulatory and Approval Risk: While some Vytex products have FDA 510(k) clearance, future product approvals depend on end-product manufacturers and regulatory processes, which carry uncertainty [S1].
• Operational Capacity Risk: With only one employee as of December 31, 2025, and a history of discontinued operations in furniture retail, the company may face challenges in scaling and executing its business plans [S1].

• Vystar Corp is based in Worcester, Massachusetts and operates in eco-friendly products for home, office, and medical sectors [S1].
• The company focuses on three main brands: Vytex, RXAIR, and Fluid Energy Conversion (FEC) [S1].
• Vystar owns patented technology to produce Vytex Natural Rubber Latex (NRL), which reduces antigenic and total protein in latex to virtually undetectable levels [S1].
• Vytex NRL is used in over 40,000 products including balloons, foams, textiles, adhesives, carpet, paints, coatings, protective equipment, sporting equipment, and healthcare products like surgical and exam gloves and condoms [S1].
• Vystar expanded Vytex into consumer bedding products such as mattresses, mattress toppers, and pillows [S1].
• RxAir is a manufacturer of air purification systems including FDA Class II medical devices that kill germs, viruses, and bacteria using UV-C light technology [S1].
• RxAir products include residential filterless air purifiers and hospital-grade HEPA filtration products, sold online and through distributors [S1].
• Fluid Energy Conversion (FEC) develops patented green energy technologies focusing on fluid mechanics and thermodynamics, with applications in water and combustion [S1].
• Vystar acquired assets of UV Flu Technologies in 2018 to create the RxAir division [S1].
• Vystar acquired assets of NHS Holdings in 2018 to move into direct product offerings made from Vytex latex [S1].
• In 2019, Vystar acquired Fluid Energy Conversion Inc. and a majority stake in Murida Furniture Co., dba Rotmans Furniture, which ceased operations in 2022 [S1].
• Vystar has a global partnership with Corrie MacColl Limited for market development and distribution of Vytex latex [S1].
• The company holds a portfolio of patents and trademarks in the US and foreign countries [S1].
• Vystar's RxAir400 product is FDA cleared as a Class II medical device, providing market credibility [S1].
• As of December 31, 2025, Vystar had one employee [S1].
• The company faces competition in the residential air purification market and natural rubber latex market from synthetic alternatives and other manufacturers [S1].
• Vystar's Vytex business depends on market acceptance and demand for Vytex NRL, which is affected by economic conditions and consumer discretionary spending [S1].
• Vytex NRL has FDA 510(k) clearance for condoms and exam gloves, but future product approvals are uncertain and depend on end-product manufacturers [S1].
• Vystar's financial snapshot as of June 30, 2026 includes cash and equivalents of $154,424, short-term investments of $127,910, current assets of $490,686, and current liabilities of $7,674,964, resulting in a current ratio of 0.06 and cash ratio of 0.04 [S2].
• Net income for the period ending June 30, 2026 was a loss of $225,293 [S2].
• Basic and diluted EPS were -$0.03 as of September 30, 2024 [S2].
• Vystar announced a binding letter of intent to acquire a stake in GoPaid.com LLC and form a strategic partnership with Capital R3alm to launch R3alm Oracle and R3alm Collectibles platform [N3][N2].
• The company reported a court victory awarding $497,439.58 in legal fees and costs against EMA Financial, Inc. [N4].
• Vystar's Vytex Cloud Bed-in-a-Box product was made available for sale and later restarted sales [N5][N6].
• Vystar introduced new RxAir-800 replacement cartridge with extended life UV-C bulb and an ultrasoft latex mattress topper with Vytex 55 density latex [N7][N8].